BackInnate Pharma S.A. Overview

Innate Pharma S.A. Receivables

Innate Pharma S.A.'s receivables is $4.6M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$4.58M
↑ 1162.84% YoYΔ $4.22M vs prior year quarter

Peer trimmed avg / median

Loading

Innate Pharma S.A. Receivables History

Loading

Innate Pharma S.A. vs. peers: Receivables Comparison

Loading

Innate Pharma S.A. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Innate Pharma S.A. (IPHYF) FAQ

As of the most recent data (June 2026), IPHYF shows a receivables of $4.6M. That compares with $360K in the prior-year period — up 1162.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IPHYF's receivables is now $4.6M (was $360K) — a 1162.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Innate Pharma S.A. is outperforming or lagging.

Tracking IPHYF's receivables over time shows whether Innate Pharma S.A. is scaling, shrinking, or reshaping that part of the business. The current reading is $4.6M That compares with $360K in the prior-year period — up 1162.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Innate Pharma S.A.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $4.6M) with ownership activity and broader fundamentals.

Innate Pharma S.A.'s receivables is $4.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.